 SAN DIEGO, CA ACCESSWIRE March 2, 2021 Nascent Biotech, Inc. OTCQB:NBIO Nascent Biotech, Nascent, or the Company, a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is excited to announce that the Company has officially received allowance for a Method-of-Use patent by the US Patent and Trademark Office USPTO for their primary asset, Pritumumab PTB. Specifically, the patent approval is related to PTBs ability to cross the Blood-Brain Barrier BBB. 